drugset / Trial / NCT05918198
Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to test the safety and efficacy of venetoclax plus CAG regimen in refractory/relapsed acute myeloid leukemia patients.
Timeline
- Start
- 2023-02-01
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Venetoclax | Small molecule | 100 mg | — |
| Subject | Venetoclax | Small molecule | 400 mg | — |
| Background | Acla | Unknown | 20 mg | — |
| Background | Cytarabine | Small molecule | 10 mg/m2 | Other |
| Background | G-CSF | Unknown | 5 ug/kg | — |